These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 31531981)

  • 1. Changes in serum TNF-like weak inducer of apoptosis (TWEAK) levels and Psoriasis Area Severity Index (PASI) scores in plaque psoriasis patients treated with conventional versus anti-TNF treatments.
    Engin B; Tanakol A; Bulut H; Songür A; Vehid HE; Gökalp E; Kutlubay Z; Özkoca D; Tüzün Y; Serdaroğlu S
    Int J Dermatol; 2020 Feb; 59(2):207-215. PubMed ID: 31531981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effectiveness of less commonly used systemic monotherapies and common combination therapies for moderate to severe psoriasis in the clinical setting.
    Takeshita J; Wang S; Shin DB; Callis Duffin K; Krueger GG; Kalb RE; Weisman JD; Sperber BR; Stierstorfer MB; Brod BA; Schleicher SM; Robertson AD; Linn KA; Shinohara RT; Troxel AB; Van Voorhees AS; Gelfand JM
    J Am Acad Dermatol; 2014 Dec; 71(6):1167-75. PubMed ID: 25260564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TWEAK levels in psoriatic patients treated with narrowband ultraviolet B and methotrexate.
    Hegazy EM; El Taieb MA; Ibrahim HM; Rageh EM; Ahmed NM; Ibrahim AK; Younis AM; Ali MA
    J Cosmet Dermatol; 2024 May; 23(5):1905-1911. PubMed ID: 38299446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum concentrations of interleukin-2 and tumour necrosis factor-α under cyclosporine versus acitretin treatment in plaque-type psoriasis.
    Akçali C; Guven EH; Kirtak N; Inaloz HS; Ozgoztasi O; Guvenc U
    J Int Med Res; 2014 Oct; 42(5):1118-22. PubMed ID: 25143337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of narrowband ultraviolet B phototherapy on serum tumour necrosis factor-like weak inducer of apoptosis (TWEAK) in patients with psoriasis.
    Myśliwiec H; Kiluk P; Myśliwiec P; Żelazowska-Rutkowska B; Baran A; Flisiak I
    Clin Exp Dermatol; 2017 Oct; 42(7):786-790. PubMed ID: 28748592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-TNF-α Drugs Differently Affect the TNFα-sTNFR System and Monocyte Subsets in Patients with Psoriasis.
    Gibellini L; De Biasi S; Bianchini E; Bartolomeo R; Fabiano A; Manfredini M; Ferrari F; Albertini G; Trenti T; Nasi M; Pinti M; Iannone A; Salvarani C; Cossarizza A; Pellacani G
    PLoS One; 2016; 11(12):e0167757. PubMed ID: 27936119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study.
    Talamonti M; Galluzzo M; Bernardini N; Caldarola G; Persechino S; Cantoresi F; Egan CG; Potenza C; Peris K; Bianchi L
    J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1737-1744. PubMed ID: 29776016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum levels of TWEAK in patients with psoriasis vulgaris.
    Bilgiç Ö; Sivrikaya A; Toker A; Ünlü A; Altınyazar C
    Cytokine; 2016 Jan; 77():10-3. PubMed ID: 26499979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequency of monoclonal gammopathy in psoriatic patients receiving anti-TNF therapy compared with patients taking conventional drugs: a cross-sectional study.
    Di Lernia V; Ficarelli E; Lallas A; Possemato N; Chiarolanza I; Salvarani C
    J Eur Acad Dermatol Venereol; 2015 Nov; 29(11):2262-3. PubMed ID: 24911670
    [No Abstract]   [Full Text] [Related]  

  • 10. Dithranol treatment of plaque-type psoriasis increases serum TNF-like weak inducer of apoptosis (TWEAK).
    Myśliwiec H; Myśliwiec P; Baran A; Flisiak I
    Adv Med Sci; 2016 Sep; 61(2):207-211. PubMed ID: 26895458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy comparison of ustekinumab between anti-tumor necrosis factor-α drug-naïve and anti-tumor necrosis factor-α drug-resistant Japanese psoriasis cases.
    Takahashi N; Noda S; Taniguchi T; Adachi M
    Int J Dermatol; 2015 Oct; 54(10):1194-8. PubMed ID: 26016819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Algorithm to select optimal systemic anti-psoriatic drugs in relation with patients' Psoriasis Area and Severity Index score for plaque psoriasis.
    Bae SH; Yun SJ; Lee JB; Kim SJ; Won YH; Lee SC
    J Dermatol; 2016 Jun; 43(6):643-9. PubMed ID: 26598783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biologic drug survival in Israeli psoriasis patients.
    Shalom G; Cohen AD; Ziv M; Eran CB; Feldhamer I; Freud T; Berman E; Oren S; Hodak E; Pavlovsky L
    J Am Acad Dermatol; 2017 Apr; 76(4):662-669.e1. PubMed ID: 28038888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biologic and Conventional Systemic Therapies Show Similar Safety and Efficacy in Elderly and Adult Patients With Moderate to Severe Psoriasis.
    Garber C; Plotnikova N; Au SC; Sorensen EP; Gottlieb A
    J Drugs Dermatol; 2015 Aug; 14(8):846-52. PubMed ID: 26267729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of biologic therapies in psoriasis vulgaris.
    Mala R; Fida M; Jorgaqi E; Vasili E
    Dermatol Ther; 2019 Jul; 32(4):e12936. PubMed ID: 30983095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adalimumab in the treatment of moderate-to-severe chronic plaque psoriasis in patients switching from other biologics.
    Sator P; Richter L; Saxinger W; Vasiljevic M; Stingl G
    J Eur Acad Dermatol Venereol; 2015 Sep; 29(9):1742-9. PubMed ID: 25665143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic antipsoriatic combination therapy with fumaric acid esters for plaque-type psoriasis: report on 17 cases.
    Wilsmann-Theis D; Frambach Y; Philipp S; Weyergraf AJ; Jacobi A; Mössner R; Gerdes S
    Dermatology; 2015; 230(2):119-27. PubMed ID: 25661583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Presence of antidrug antibodies correlates inversely with the plasma tumor necrosis factor (TNF)-α level and the efficacy of TNF-inhibitor therapy in psoriasis.
    Kui R; Gál B; Gaál M; Kiss M; Kemény L; Gyulai R
    J Dermatol; 2016 Sep; 43(9):1018-23. PubMed ID: 26892625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany.
    Augustin M; McBride D; Gilloteau I; O'Neill C; Neidhardt K; Graham CN
    J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2191-2199. PubMed ID: 29729105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic evaluation of systemic therapies for moderate to severe psoriasis.
    Sizto S; Bansback N; Feldman SR; Willian MK; Anis AH
    Br J Dermatol; 2009 Jun; 160(6):1264-72. PubMed ID: 19120346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.